AnaptysBio, Inc. (ANAB)
ANAB moved a median of -0.51% 30 minutes after news, and -0.41% by the close. How ANAB actually reacts to news — the realized, point-in-time move the market made, measured across 344 labeled events over the last three years with zero look-ahead.
ANAB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 342 |
| 30-min | -0.51% | 44% | 342 |
| 60-min | +0.09% | 51% | 342 |
| to close | -0.41% | 43% | 341 |
| Middle 50% of ANAB reactions | -1.40% to +1.56% |
|---|---|
| Median reaction (30-min) | -0.51% |
| Measured reactions | 344 |
Half of all AnaptysBio, Inc. news events land between -1.40% and +1.56% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ANAB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | -2.40% | 36% | -3.68% |
| Analyst downgrades | 11 | -0.06% | 46% | +3.39% |
| Coverage initiations | 28 | -0.69% | 46% | -0.32% |
| Rating reiterations | 94 | +0.72% | 63% | +0.16% |
| Price-target raises | 21 | +0.64% | 52% | +0.24% |
| Price-target cuts | 12 | +0.17% | 50% | +0.70% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how ANAB ranks against every other measured name →
That’s how ANAB usually reacts — get an email when it moves on news →Email me when ANAB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANAB's baseline. Nothing else.
Recent ANAB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.17% | -2.09% | |
| Form 10-KT ANAPTYSBIO, INC For: Jun 30 | SEC filing · Form 10-KT | SEC EDGAR | +0.17% | -2.09% | |
| Form 8-K ANAPTYSBIO, INC For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | -2.09% | |
| Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +2.73% | -0.52% | |
| Form 8-K ANAPTYSBIO, INC For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | -1.74% | |
| Form 8-K ANAPTYSBIO, INC For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -1.37% | -1.37% | |
| Form ARS ANAPTYSBIO, INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.04% | +1.81% | |
| Form DEF 14A ANAPTYSBIO, INC For: Jun 29 | SEC filing · Form DEF | SEC EDGAR | -1.04% | +1.81% | |
| Form DEFA14A ANAPTYSBIO, INC | SEC filing · Form DEFA14A | SEC EDGAR | -1.04% | +1.81% | |
| Form 8-K ANAPTYSBIO, INC For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +2.03% | +0.34% | |
| Form 8-K ANAPTYSBIO, INC For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -2.16% | -4.06% | |
| Form 8-K ANAPTYSBIO, INC For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -1.29% | |
| Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -5.99% | -3.71% | |
| Form 10-Q ANAPTYSBIO, INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.99% | -3.71% | |
| Form 8-K ANAPTYSBIO, INC For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -5.99% | -3.71% | |
| Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors | Press release | GlobeNewswire | +1.03% | -2.62% | |
| Form 8-K ANAPTYSBIO, INC For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | -2.57% | |
| Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference | Press release | GlobeNewswire | +0.86% | -2.33% | |
| Form 10-K/A ANAPTYSBIO, INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.44% | -4.33% | |
| Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim | Press release | GlobeNewswire | +7.02% | +11.07% | |
| Form 8-K/A ANAPTYSBIO, INC For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | +11.19% | |
| Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | Press release | GlobeNewswire | +4.74% | +13.53% | |
| Form 8-K ANAPTYSBIO, INC For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | +1.45% | |
| Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update | Press release | GlobeNewswire | -0.80% | -11.91% | |
| Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics | Press release | GlobeNewswire | -0.80% | -11.91% | |
| First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement | Press release | GlobeNewswire | -0.80% | -11.91% | |
| Form 8-K ANAPTYSBIO, INC For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -0.80% | -11.91% | |
| Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -2.83% | +7.97% | |
| Form 10-K ANAPTYSBIO, INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.83% | +7.97% | |
| Form 8-K ANAPTYSBIO, INC For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -2.83% | +7.97% | |
| Anaptys Announces Participation at Upcoming Investor Conferences | Press release | GlobeNewswire | +3.60% | +1.68% | |
| Form 8-K ANAPTYSBIO, INC For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | +10.08% | |
| Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | Press release | GlobeNewswire | +2.43% | +4.49% | |
| Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.64% | -0.96% | |
| Form 8-K ANAPTYSBIO, INC For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | -0.77% | -2.37% | |
| Anaptys Announces Participation in December Investor Conferences | Press release | GlobeNewswire | +0.92% | +0.38% | |
| Anaptys Announces $100 Million Stock Repurchase Plan | Press release | GlobeNewswire | +3.09% | +16.67% | |
| Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary | Press release | GlobeNewswire | +3.09% | +16.67% | |
| Form 8-K ANAPTYSBIO, INC For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +3.09% | +16.67% | |
| Form 8-K ANAPTYSBIO, INC For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | +3.09% | +16.67% | |
| Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis | Press release | GlobeNewswire | +6.25% | +6.19% | |
| Form 8-K ANAPTYSBIO, INC For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +6.25% | +6.19% | |
| Anaptys Announces Participation in November Investor Conferences | Press release | GlobeNewswire | -6.04% | -8.21% | |
| Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.04% | -8.21% | |
| Form 10-Q ANAPTYSBIO, INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.04% | -8.21% | |
| Form 8-K ANAPTYSBIO, INC For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -6.04% | -8.21% | |
| Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation | Press release | GlobeNewswire | -1.29% | -4.72% | |
| Form 8-K ANAPTYSBIO, INC For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +5.53% | +8.69% | |
| Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 | Press release | GlobeNewswire | +0.58% | -0.15% | |
| Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 | Press release | GlobeNewswire | +8.85% | +19.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANAB section they belong to.
Where else ANAB is measured.
ANAB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Avid Bioservices, Inc. (CDMO) | 354 | 0.00% | 49% |
| Celcuity Inc. (CELC) | 354 | +0.13% | 52% |
| REGENERX BIOPHARMS INC (RGRX) | 343 | 0.00% | 36% |
| Allena Pharmaceuticals, Inc. (ALNA) | 342 | 0.00% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AnaptysBio, Inc.'s median reaction calculated?
Every labeled ANAB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 344 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of ANAB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ANAB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.